Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.
- DOI
- 10.1016/j.ejca.2026.116833
- Published
- 2026 Jul 26
- Container
- European journal of cancer (Oxford, England : 1990)
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.ejca.2026.116833,
title = {Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.},
author = {Nelson A and Alghaib S and Björkström K and Isaksson K and Krabbe E and Orme S and Kadefors M and Wallander M and Bjursten S and Ullenhag GJ and Carneiro A and Helgadottir H and Ny L and Olofsson Bagge R},
year = {2026},
journal = {European journal of cancer (Oxford, England : 1990)},
doi = {10.1016/j.ejca.2026.116833},
url = {https://doi.org/10.1016/j.ejca.2026.116833}
}RIS
TY - JOUR TI - Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study. AU - Nelson A AU - Alghaib S AU - Björkström K AU - Isaksson K AU - Krabbe E AU - Orme S AU - Kadefors M AU - Wallander M AU - Bjursten S AU - Ullenhag GJ AU - Carneiro A AU - Helgadottir H AU - Ny L AU - Olofsson Bagge R PY - 2026 JO - European journal of cancer (Oxford, England : 1990) DO - 10.1016/j.ejca.2026.116833 UR - https://doi.org/10.1016/j.ejca.2026.116833 ER -
APA
A, N., S, A., K, B., K, I., E, K., S, O., M, K., M, W., S, B., GJ, U., A, C., H, H., L, N., & R, O. B. (2026). Time of day of neoadjuvant immune checkpoint inhibitor administration is associated with survival but not pathological response in resectable stage III-IV melanoma: A retrospective cohort study.. European journal of cancer (Oxford, England : 1990). https://doi.org/10.1016/j.ejca.2026.116833
Source records
- pubmed · retrieved 2026-09-26T05:00:19.234Z